Saturday 17 October 2026
Export A’s income statement to Excel — free account
Agilent Technologies, Inc.
A Healthcare Diagnostics & Research
Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024. In the quarter to July 2026, revenue grew 8.06%, EPS grew 8.47%, free cash flow grew 69.5% and total debt rose 8.81%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
172.96
2.59
−1.48%
Follow A
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
31.96 | 29.82 | 23.16 | 27.18 |
P/S ratio |
5.98 | 5.42 | 4.51 | 5.29 | |
P/FCF ratio |
36.02 | 38.51 | 29.92 | 30.75 | |
P/Operating CF |
76.27 | 142.97 | 117.64 | 75.18 | |
P/B ratio |
6.17 | 5.55 | 4.58 | 5.30 | |
Price to Tangible BV |
22.80 | 19.18 | 14.61 | 27.34 | |
EV/Sales |
6.16 | 5.61 | 4.68 | 5.55 | |
EV/EBITDA |
24.24 | 22.78 | 18.47 | 21.42 | |
EV/Operating CF |
27.47 | 28.37 | 23.30 | 25.42 | |
EV/FCF |
37.11 | 39.81 | 31.06 | 32.24 | |
Quick Ratio |
1.40 | 1.47 | 1.46 | 1.41 | |
Current Ratio |
1.96 | 2.07 | 2.10 | 2.05 | |
Net Debt/EBITDA |
2.45 | 3.08 | 2.67 | 3.70 | |
Debt/Assets |
23.96% | 23.80% | 23.35% | 26.10% | |
Debt/Equity |
0.45 | 0.44 | 0.43 | 0.50 | |
Asset Turnover |
0.57 | 0.57 | 0.57 | 0.56 | |
Operating CF/Net income |
1.26 | 0.88 | 0.82 | 1.43 | |
Capex/Depreciation |
(1.31) | (1.39) | (1.13) | (1.21) | |
Interest Coverage |
16.41 | 14.12 | 15.96 | 15.31 | |
Research and Development Expense of Revenue |
6.39% | 6.51% | 6.87% | 6.55% | |
Selling, General and Administrative Expense of Revenue |
23.00% | 26.47% | 25.34% | 25.29% | |
Intangible Assets out of Total Assets |
0.39 | 0.38 | 0.37 | 0.43 | |
Share Based Compensation of Revenue |
1.40% | 2.28% | 1.74% | 1.70% | |
Graham Net Nets |
(0.03) | (0.03) | (0.04) | (0.05) | |
Graham Number |
49.46 | 49.93 | 53.25 | 54.68 | |
Earnings Yield |
3.13% | 3.35% | 4.32% | 3.68% | |
Free Cash Flow Yield |
2.78% | 2.60% | 3.34% | 3.25% | |
Revenue per Share |
6.55 | 6.35 | 6.51 | 6.66 | |
Operating CF per Share |
1.92 | 0.95 | 0.98 | 1.84 | |
Capex per Share |
(0.33) | (0.33) | (0.27) | (0.28) | |
Free Cash Flow per Share |
1.59 | 0.62 | 0.71 | 1.56 | |
Cash per Share |
6.30 | 6.21 | 6.41 | 6.23 | |
Shareholders Equity per Share |
23.74 | 24.41 | 25.26 | 26.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
23.74 | 24.41 | 25.26 | 26.11 | |
Free Cash Flow |
452.00 | 175.00 | 201.00 | 439.00 | |
Working Capital |
2,247.00 | 2,381.00 | 2,494.00 | 2,404.00 | |
Capital Expenditures |
(93.00) | (93.00) | (76.00) | (80.00) | |
Net Current Asset Value |
(1,392.00) | (1,290.00) | (1,180.00) | (1,911.00) | |
EV/EBIT |
28.96 | 27.20 | 21.76 | 24.96 | |
Capex to Sales |
0.05 | 0.05 | 0.04 | 0.04 | |
Price to Operating Income |
28.10 | 26.32 | 20.96 | 23.81 | |
| Other line items | |||||
Average Receivables |
1,405.50 | 1,424.50 | 1,432.00 | 1,430.00 | |
Average Payables |
555.00 | 574.50 | 566.00 | 569.00 | |
Average Inventory |
998.50 | 1,028.00 | 1,040.00 | 1,065.50 | |
Average Assets |
12,286.50 | 12,363.50 | 12,611.50 | 13,096.50 | |
Average Common Equity |
6,319.50 | 6,467.50 | 6,629.00 | 6,866.50 |
Columns are period end dates